News Stocks 

Aprea Therapeutics’ stock opens 3.1% above IPO price, then rises further

“APRE, +10.67% got off to a positive start as a public company Thursday, as the first trade of the cancer treatment developer’s stock was 3.1% above its $15 initial public offering price” writes Reporter Editor for The biopharmaceutical company sold 5 million shares in the IPO to raise $75 million, and was valued at $288.15 million.The IPO priced late Wednesday in the middle of the expected range of $14 to $16.

Related posts